TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← All Stock Lists
▌Top Stocks · CLINICAL RESEARCH AND PHARMA SERVICES·Updated November 13, 2026

Clinical Research and Pharma Services Stocks That Beat Estimates: 3 Picks

A three-stock countdown explores CRO, preclinical, analytics and pharma-services exposure, with Charles River and IQVIA among the names assessed.

Top Stocks · CLINICAL RESEARCH AND PHARMA SERVICESUpdated November 13, 2026
CRLIQV+1 locked
Last refreshed November 13, 2026·8 min read
Clinical Research and Pharma Services Stocks That Beat Estimates: 3 Picks

Clinical research and pharma services are entering a more constructive, though still selective, phase. After biotech funding pressure and slower sponsor spending weighed on development activity, investors are looking for signs of normalized trial demand, better visibility and durable outsourcing economics. Pharmaceutical and biotechnology companies continue to use external providers to control costs, shorten development timelines and access specialized expertise. That makes the sector an important read-through on whether drug-development activity is stabilizing, even as spending recovery remains uneven across therapeutic areas and stages.

The opportunity spans contract research organizations, contract development and manufacturing organizations, early-phase and bioanalytical specialists, clinical trial site networks and software or data platforms. Rising trial complexity, faster-enrollment requirements and technology-enabled workflows are supporting demand for providers that can improve site activation, data quality and operating efficiency. Full-service and integrated offerings are especially relevant because sponsors increasingly want fewer handoffs across development. Fortrea’s September 2026 agreement to acquire Worldwide Clinical Trials’ early-phase services division for $45 million also illustrates how providers are using acquisitions to deepen exposure to higher-value parts of the development chain.

This three-stock countdown examines companies with distinct positions across that ecosystem, from preclinical testing and safety assessment to global clinical research, analytics and integrated development services. The selections appear in countdown order, beginning with the third-ranked name and progressing to the best pick at No. 1. The ranking emphasizes depth of exposure to clinical research and pharma services first, then weighs business fundamentals such as growth, profitability, valuation and earnings execution. That approach favors companies with direct theme exposure while recognizing that their financial profiles differ materially.

The screen was limited to U.S.-listed companies with market capitalizations above $500 million and usable operating, valuation and earnings data. Names were ranked first by how directly and extensively their businesses participate in clinical research and pharma services, then by fundamentals including margins, return metrics, revenue and earnings growth, valuation, analyst consensus and recent earnings delivery. The list is presented as a countdown from No. 3 to No. 1, so the best pick appears at the end. Grades are our composite quality assessments rather than investment recommendations, and analyst targets are reported as supplied rather than treated as forecasts.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

3. CRL — Charles River Laboratories

Market cap: $16.3B · Quality grade: C+ · Analyst consensus: 4.3529/5 (avg target $346)

What they do. The company provides drug discovery, non-clinical development and safety-testing services across North America, Europe, Asia-Pacific and other international markets. Its Research Models and Services segment supplies rodents, engineered models, diagnostics and related support, while Discovery and Safety Assessment provides in vitro and in vivo discovery, toxicology, pathology, bioanalysis, pharmacokinetics and other preclinical work. Manufacturing Solutions adds quality-control testing and contract development and manufacturing, giving Charles River a broad platform around the preclinical and development chain.

Why it fits. Charles River has particularly deep exposure to the preclinical side of the theme, where research models, discovery services and safety assessment help sponsors prepare candidates for clinical testing. Its bioanalysis, drug metabolism and pharmacokinetics capabilities also connect laboratory work with the evidence required to advance development programs, while its manufacturing and quality-testing activities broaden the pharma-services exposure beyond a single CRO niche.

Numbers that matter. Gross margin is 35.1%, operating margin is 0.1427 and net margin is 0.0101, while ROE is 0.0127 and ROA is 0.0474. Revenue growth was -0.022 year over year, a sign that the normalization in sponsor activity has not translated into broad-based top-line momentum for the company. The reported earnings-growth metric is 5.236. Valuation data list a trailing P/E of 370.4457 and a forward P/E of 27.7778, making the earnings base and the difference between trailing and forward measures important considerations.

Recent momentum. Charles River delivered EPS of $3.09 against an estimate of $2.98 in the quarter reported on November 4, 2026, a 3.7% surprise. It has beaten estimates in all eight quarters shown, including an 11.0% surprise in the prior quarter. Analyst consensus is 4.3529, with three buy ratings and two hold ratings in the supplied breakdown; the average analyst target is $346.0714.

2. IQV — IQVIA Holdings Inc

Market cap: $45.2B · Quality grade: B · Analyst consensus: 4.7/5 (avg target $312)

What they do. The company provides clinical research services, commercial insights and healthcare intelligence through Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Its offering includes cloud applications, real-world evidence, consulting, clinical monitoring, trial support, project management, central laboratory, genomic, bioanalytical, vaccine and biomarker services. That combination gives IQVIA a diversified revenue model spanning outsourced research, technology and analytics, rather than relying solely on individual trial-management contracts.

Why it fits. IQVIA is one of the clearest matches for the theme because its Research & Development Solutions segment directly addresses clinical monitoring, trial support, patient and site services and laboratory work. Its technology and analytics platform further aligns with the shift toward data-enabled workflows, real-world evidence and more efficient decision-making across development and commercialization.

Numbers that matter. IQVIA reports a 33.1% gross margin, a 0.1389 operating margin and a 0.0805 net margin, with ROE of 0.2139 and ROA of 0.0508. Revenue growth was 0.08 year over year and earnings growth was 0.088, providing a stronger growth profile than a business experiencing outright revenue contraction. The valuation data show a trailing P/E of 33.3978 and a forward P/E of 18.9753. Its scale, technology exposure and breadth of services support the theme, although the valuation still depends on continued execution.

Recent momentum. IQVIA reported EPS of $2.95 versus an estimate of $2.94 on October 27, 2026, a 0.3% surprise. The company has beaten estimates in all eight quarters shown, although the latest beats have generally been narrow. Analyst consensus is 4.7, with two buy ratings and two hold ratings in the supplied breakdown, and the average analyst target is $311.8889.

Pick #1Premium members only

Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Methodology

This monthly screen covers U.S.-listed companies with market capitalizations above $500 million and meaningful exposure to clinical research or adjacent pharma services. The ranking is based first on depth of thematic exposure, including participation in CRO, CDMO, preclinical, laboratory, clinical-site, analytics or enabling-technology activities. Business fundamentals then determine the order, with consideration given to profitability, return metrics, revenue and earnings growth, valuation, analyst consensus and recent earnings performance. The article is refreshed monthly to incorporate updated financial data, consensus information and earnings history, while keeping the countdown format from No. 3 to No. 1.

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌For Active Investors

Don't trade alone.

Get market intelligence delivered daily.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More stock lists

More to read

All articles
7 Zero Trust Security Stocks Worth Watching in November 2026

7 Zero Trust Security Stocks Worth Watching in November 2026

This countdown spans identity, SASE, endpoint, cloud and network-security businesses across the zero trust security landscape.

Nov 18·13 min
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026

Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Nov 18·11 min
Independent Power Producers Stocks to Own in 2026: 5 Names

Independent Power Producers Stocks to Own in 2026: 5 Names

A five-stock countdown spans merchant, nuclear, renewable, coal, gas and hybrid power platforms, with Hallador, Brookfield and Talen offering distinct exposures.

Nov 3·10 min